How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?

Authors :: True LD
Chen DL
Source :: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 01; Vol. 27 (13), pp. 3512-3514. Date of Electronic Publication: 2021 Apr 23.
Publication Year :: 2021
Abstract: Current techniques for imaging prostate cancer (CT, MRI, and PET agents <superscript>18</superscript> F-fluorodeoxyglucose, <superscript>11</superscript> C-choline, <superscript>11</superscript> C-acetate, and <superscript>18</superscript> F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent <superscript>68</superscript> Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT. See related article by Morris et al., p. 3674 .<br /> (©2021 American Association for Cancer Research.)

Subjects :: Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms diagnostic imaging

Language :: English
ISSN :: 1557-3265
Volume :: 27
Issue :: 13
Database :: MEDLINE
Journal :: Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Type :: Academic Journal
Accession number :: 33893158
Full Text :: https://doi.org/10.1158/1078-0432.CCR-21-0749